Eagle Pharmaceuticals (EGRX): Notes From Management NDR - Piper Jaffray

October 14, 2016 10:11 AM EDT
Get Alerts EGRX Hot Sheet
Price: $76.57 +0.49%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade EGRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) after traveling with senior management to meet with investors.

The analyst believes that EGRX is well positioned for significant value creation, driven by royalties from Teva on Bendeka through 2019 (and meaningful cash flows thereafter), along with growing contribution from pipeline assets (Ryanodex; a ready-touse (RTU) form of Eli Lilly’s Alimta (pemetrexed)).

No change to the $91 PT which represents a P/E of 12x 2017 earnings.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $63.56 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Earnings

Add Your Comment